Kane Biotech (TSE:KNE) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Kane Biotech has gained attention with a new publication in Pathogens journal and multiple conference presentations, highlighting the potential of their enzyme DispersinB® as a broad-spectrum antibiofilm agent. The company’s ongoing research efforts are showcased through presentations on the antibiofilm properties of revyve™ Antimicrobial Wound Gel Spray, signalling a commitment to advancing biofilm science and developing effective treatments for chronic wound infections.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue